25 LLC’s Editas Medicine EDIT Stock Holding History

25 LLC’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-101	Closed	-$904	–	184
2023 Q2	$904	Hold	101	–	–	﹤0.01%	305
2023 Q1	$972	Buy	+101	New	+$898	﹤0.01%	236

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

25 LLC's EDIT Position: Q3 2023 in Review

25 LLC sold out of Editas Medicine (EDIT) in Q3 2023, closing a stake of 101 shares — an estimated $904 sold.

25 LLC first reported a position in EDIT in Q1 2023 and held it in 2 quarters. The position peaked at $972 in Q1 2023. 220 funds tracked by Wall St. Rank hold EDIT as of Q3 2023.

25 LLC reported no remaining Editas Medicine position as of Q3 2023 after selling out during the quarter.
25 LLC sold 101 Editas Medicine shares in Q3 2023, an estimated $904.
25 LLC first reported a position in Editas Medicine in Q1 2023 and held it in 2 quarters.
25 LLC's Editas Medicine position peaked at $972 in Q1 2023.
220 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.